1-Methyl-2-(1'-hydroxyethyl)piperidine | 135938-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methyl-2-(1'-hydroxyethyl)piperidine
• 英文别名: 1-(1-methyl-[2]piperidyl)-ethanol；1-(1-Methyl-[2]piperidyl)-aethanol；(1-Methyl-2-piperidyl)-1-ethanol；1-(1-methylpiperidin-2-yl)ethanol
• CAS: 135938-67-9
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: QRJVCFVPXDIZAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Methyl-2-(1'-hydroxyethyl)piperidine 在 chromium(VI) oxide 、 五氯化磷 、 硫酸 、 sodium amide 、 三氯氧磷 作用下， 反应 14.5h， 生成 1-Methyl-2-(3'-oxy-3',3'-diphenyl-1'-propinyl)piperidine
  参考文献：
  名称：

  Acetylenic aminoalcohols VIII. 3, 3-Diphenyl-3-hydroxypropynylpiperidines

  摘要：

  DOI：

  10.1007/bf00760704
• 作为产物：
  描述：

  2-乙酰基吡啶 在 甲酸 、 水 、 溶剂黄146 、 铂 作用下， 生成 1-Methyl-2-(1'-hydroxyethyl)piperidine
  参考文献：
  名称：

  Hess; Corleis, Chemische Berichte, 1921, vol. 54, p. 3019

  摘要：

  DOI：

文献信息

• Indole derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05124324A1

  公开（公告）日：1992-06-23

  Disclosed are compounds of formula I ##STR1## wherein R.sub.1 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group, benzyl or an indolyl carbonyl group, R.sub.2 is a saturated or unsaturated 5- or 8-membered heterocyclic group containing as a hetero atom one or more nitrogen atoms, the heterocyclic group is optionally substituted at an N or C atom by a C.sub.1 -C.sub.6 alkyl or aralkyl group, n is an integer of 1 to 5 and one or more hydrogen atoms, in an alkylene chain --(CH.sub.2).sub.n -- are optionally substituted by a C.sub.1 -C.sub.6 alkyl, phenyl and/or hydroxyl group, physiologically acceptable salts and quaternary ammonium salts thereof. The compounds are selective antagonists of 5-HT.sub.3 receptors and are useful in the treatment of psychotic disorders, neurotic diseases, gastric stasis symptoms, gastrointestinal disorders, nausea and vomiting.

  公开的是I式化合物，其中R.sub.1是氢原子、C.sub.1 -C.sub.6烷基、苄基或吲哚基酰基，R.sub.2是含有一个或多个氮原子的饱和或不饱和5-或8-成员杂环基团，该杂环基团在N或C原子上可以被C.sub.1 -C.sub.6烷基或芳基烷基取代，n是1到5的整数和一个或多个氢原子，在烷基链--(CH.sub.2).sub.n --中的一个或多个氢原子可以被C.sub.1 -C.sub.6烷基、苯基和/或羟基取代，其生理学上可接受的盐和季铵盐。这些化合物是5-HT.sub.3受体的选择性拮抗剂，可用于治疗精神障碍、神经病、胃排空延迟症状、胃肠道疾病、恶心和呕吐。
• Piperidine derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05246945A1

  公开（公告）日：1993-09-21

  Disclosed are compounds of formula (I) ##STR1## in which A is ##STR2## The compounds are selective antagonists of 5HT at 5-HT.sub.3 receptors and useful in the treatment of psychotic disorders, neurotic diseases, gastric stasis symptoms, gastrointestinal disorders, nausea and vomiting.

  本发明涉及式(I)的化合物：##STR1## 其中A是##STR2## 这些化合物是5-HT3受体的选择性拮抗剂，可用于治疗精神障碍、神经病、胃排空障碍症状、胃肠道疾病、恶心和呕吐。
• Polyorganosiloxane having a quaternary salt at its one terminal and percutaneous absorption-promoting agent
  申请人：SAGAMI CHEMICAL RESEARCH CENTER

  公开号：EP0484857A2

  公开（公告）日：1992-05-13

  A polyorganosiloxane having a quaternary salt at its one terminal, of the following formula (I): wherein A is or X is a counter anion in the quaternary salt; each of R1 to R5 which may be the same or different, is an alkyl group, a substituted alkyl group or a phenyl group; Y is a C1 -6 linear or branched bivalent alkylene or oxyalkylene group; and n is an integer of at least 1, provided that when n is 2 or more, the plurality of each of R4 and R5 may be the same or different, wherein each of R6 to R8 which may be the same or different, is an alkyl group, a substituted alkyl group or a phenyl group, or R6 to R8 together form a ring and/or an unsaturated bond; R is a C1 -6 alkyl group or a phenyl group; m is an integer of from 0 to 3, provided that when m is 2 or 3, the plurality of R may be the same of different; and each of R9 to R11 which may be the same or different, is a phenyl group, a benzyl group or a C1 -6 alkyl group.

  一种聚有机硅氧烷，其一个末端含有下式（I）的季铵盐： 其中 A 是 或 X 是季盐中的反阴离子；R1 至 R5（可以相同或不同）是烷基、取代烷基或苯基；Y 是 C1 -6 直链或支链二价亚烷基或氧亚烷基；且 n 至少为 1 的整数，条件是当 n 为 2 或更多时，R4 和 R5 的复数可以相同或不同，其中 R6 至 R8 可以相同或不同，每个 R6 至 R8 是烷基、取代烷基或苯基，或 R6 至 R8 一起形成一个环和/或不饱和键；R 是 C1 -6 烷基或苯基；m 是 0 至 3 的整数，但当 m 为 2 或 3 时，多个 R 可以相同或不同；R9 至 R11 中的每个 R 可以相同或不同，是苯基、苄基或 C1 -6 烷基。
• AMINATED POLYSILAZANE AND PROCESS FOR THE PREPARATION THEREOF
  申请人：Tonen Corporation

  公开号：EP1002824A1

  公开（公告）日：2000-05-24

  An amine residue-containing polysilazane having a number average molecular weight of 100-100,000 and having a molecular chain containing a silazane structure represented by the general formula (I) shown below and/or a silazane structure represented by the general formula (II) shown below: wherein R1 and R2 each stand for hydrogen, a hydrocarbyl group or a hydrocarbyl group-containing silyl group, A and A2 each stand for a divalent hydrocarbyl group, B stands for an N-hydrocarbyl group-substituted amine residue or a cyclic amine residue, B2 stands for a divalent linear amine residue or a divalent cyclic amine residue and p and q are each 0 or 1. The above polysilazane may be obtained by reacting a polysilazane with a mono- and/or dihydroxyl compound having an amine residue in an inert organic solvent containing no active hydrogen.

  一种含胺残基的聚硅氮烷，其平均分子量为 100-100,000，分子链中含有下图所示通式(I)所代表的硅氮烷结构和/或下图所示通式(II)所代表的硅氮烷结构： 其中 R1 和 R2 分别代表氢、烃基或含烃基的硅基，A 和 A2 分别代表二价烃基，B 代表 N-烃基取代的胺残基或环胺残基，B2 代表二价线性胺残基或二价环胺残基，p 和 q 分别为 0 或 1。上述聚硅氮烷可通过在不含活泼氢的惰性有机溶剂中使聚硅氮烷与具有胺残基的单羟基和/或二羟基化合物反应而获得。
• New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2383259A1

  公开（公告）日：2011-11-02

  The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U,V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及通式 I 的化合物 其中基团 B、k、L、U、V、W、X、Y、Z、R1、R2 具有权利要求 1 所述的含义。此外，本发明还涉及含有至少一种根据本发明的化合物的药物组合物。由于其 MCH 受体拮抗活性，根据本发明的药物组合物适用于治疗代谢紊乱和/或饮食失调，特别是肥胖症、贪食症、厌食症、食欲过盛和糖尿病。